Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 - 60 Years: A “Campus CML” Study

Blood (2024) 144 (Supplement 1): 1772.

https://doi.org/10.1182/blood-2024-207175

Published: 2024

Journal Articles

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

Blood (2024) 143 (7): 592–596.

https://doi.org/10.1182/blood.2023022080

Published: 2024

Includes: Supplemental data

Journal Articles

Real-Life Data of Bosutinib Treatment for Chronic Myeloid Leukemia: The Multi-Center Experience of the Gruppo Di Miglioramento Sicilia-Calabria

Marco Santoro, Sabina Russo, Iolanda Donatella Vincelli, Emilia Cotzia, Stefana Impera, Vincenzo Leone, Luciano Levato, Francesco Mendicino, Alessandra Malato, Mineo Giuseppe, Laura Nocilli, Ferdinando Porretto, Bruno Martino, Sergio Siragusa, Carmela Anna Maria Tomaselli

Blood (2023) 142 (Supplement 1): 6375.

https://doi.org/10.1182/blood-2023-185120

Published: 2023

Journal Articles

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Younger Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Blood (2023) 142 (Supplement 1): 1811.

https://doi.org/10.1182/blood-2023-188934

Published: 2023

Journal Articles

Carfilzomib-Lenalidomide-Dexamethasone (KRd) Vs. Lenalidomide-Dexamethasone (Rd) in Newly Diagnosed Fit or Intermediate-Fit Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation (Phase III EMN20 Trial): Analysis of Sustained Undetectable Minimal Residual Disease (MRD)

Blood (2023) 142 (Supplement 1): 205.

https://doi.org/10.1182/blood-2023-177673

Published: 2023

Journal Articles

Efficacy of Frontline Treatment with Initial Low-Dose Tyrosine-Kinase Inhibitors in Elderly Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Blood (2023) 142 (Supplement 1): 3176.

https://doi.org/10.1182/blood-2023-186406

Published: 2023

Journal Articles

Salvage Autologous Stem Cell Transplant for the Treatment of First Relapse Multiple Myeloma: Evidence of Its Clinical Role from a Multicenter Italian Study

Blood (2023) 142 (Supplement 1): 2226.

https://doi.org/10.1182/blood-2023-181233

Published: 2023

Journal Articles

Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A "Campus CML" Study

Blood (2022) 140 (Supplement 1): 3920–3922.

https://doi.org/10.1182/blood-2022-164790

Published: 2022

Journal Articles

Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in Transplant-Ineligible Real-Life Multiple Myeloma Patients: Updated Results of the Randomized Phase IV Real MM Trial

Blood (2022) 140 (Supplement 1): 1814–1816.

https://doi.org/10.1182/blood-2022-162178

Published: 2022

Journal Articles

Biological Significance and Prognostic Value of Cytogenetics in 160 Patients with Multiple Myeloma: Predictivity of 13 and/or 14 Monosomies

Jolanda Donatella Vincelli, Antonio Scopelliti, Angela Violi, Corrado Mammi', Maria Grazia D'Errigo, Irene Bova, Bianca Oliva, Cristina Garreffa, Massimo Martino, Stefania Ciolli, Bruno Martino

Blood (2021) 138 (Supplement 1): 4735.

https://doi.org/10.1182/blood-2021-150620

Published: 2021

Journal Articles

Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study

Blood (2021) 138 (Supplement 1): 3617.

https://doi.org/10.1182/blood-2021-151538

Published: 2021

Journal Articles

Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-141077

Published: 2020

Journal Articles

Impact of Gain and Amplification of 1q in Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Based Treatment in the Forte Trial

Blood (2020) 136 (Supplement 1): 38–40.

https://doi.org/10.1182/blood-2020-137060

Published: 2020

Journal Articles

A Patient with Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia and Multiple Myeloma

Iolanda Donatella Vincelli, Patrizia Cufari, Carmelo Toscano, Al Sayyad Said, Mauro Campello, Giuseppina Caruso, Maria Grazia D'Errigo, Irene Bova, Corrado Mammi', Stefania Ciolli, Massimo Martino, Bianca Oliva, Cristina Garreffa, Bruno Martino

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-141974

Published: 2020

Journal Articles

Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia

Valentina Griggio, Candida Vitale, MD PhD, Chiara Salvetti, MD, Francesca Romana Mauro, MD, Daniela Pietrasanta, MD, Iolanda Donatella Vincelli, Lydia Scarfo, MD, Giovanni Del Poeta, MD, Gianluca Gaidano, MD PhD, Valter Gattei, MD, Robin Foà, MD, Mario Boccadoro, Marta Coscia, MD PhD

Blood (2019) 134 (Supplement_1): 3031.

https://doi.org/10.1182/blood-2019-125617

Published: 2019

Journal Articles

Tumor Circulating Plasma Cells Detected By Flow Cytometric Single Platform Method Correlate with Clinical Response to Therapy and Unfavorable Patients' Characteristics

Blood (2019) 134 (Supplement_1): 4357.

https://doi.org/10.1182/blood-2019-122657

Published: 2019

Journal Articles

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Alessandra Pompa, Concetta Conticello, MD, Diana Giannarelli, PhD, Loredana Pettine, MD, Laura Paris, MD, Lucia Tognazzi, Magda Marcatti, MD, Elisabetta Antonioli, MD, Francesca Fioritoni, MD, Angela Bonalumi, MD, Silvia Mangiacavalli, Paola Bertazzoni, Iolanda Donatella Vincelli, MD, Daniele Derudas, MD, Agostina Siniscalchi, Sara Pezzatti, MD, Renato Zambello, Annalisa Citro, MD, Angelo Belotti, Alessandra Lombardo, MD, Federico Vozella, MD, Adelina Sementa, MD, Ugo Consoli, MD, Alfredo Molteni, MD, Niccolò Frungillo, MD, Massimo Gentile, MD, Gabriele Buda, MD PhD, Sara Aquino, Salvatore Palmieri, Velia Bongarzoni, MD, Alessandro Inzoli, MD, Valeria Ferla, MD, Francesca Gaia Rossi, MD, Valerio Leotta, MD, Alessandra Romano, MD PhD, Federica Elia, MD, Vittorio Del Fabro, MD, Guido Montanaro, MD, Francesca Cavallaro, MD, Monica Galli, Luca Baldini, MD PhD

Blood (2019) 134 (Supplement_1): 5555.

https://doi.org/10.1182/blood-2019-125098

Published: 2019

Journal Articles

Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia

Valentina Griggio, Candida Vitale, MD, Maria Todaro, PhD, Francesca Romana Mauro, Chiara Salvetti, MD, Daniela Pietrasanta, Iolanda Donatella Vincelli, MD, Lydia Scarfo, MD, Giovanni Del Poeta, MD, Gianluca Gaidano, MD PhD, Valter Gattei, MD, Robin Foà, MD, Mario Boccadoro, MD, Marta Coscia, MD

Blood (2018) 132 (Supplement 1): 4412.

https://doi.org/10.1182/blood-2018-99-116068

Published: 2018

Journal Articles

Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials

Blood (2018) 132 (Supplement 1): 2023.

https://doi.org/10.1182/blood-2018-99-115340

Published: 2018

Journal Articles

Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)

Blood (2018) 132 (Supplement 1): 121.

https://doi.org/10.1182/blood-2018-99-112093

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 - 60 Years: A “Campus CML” Study

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

Real-Life Data of Bosutinib Treatment for Chronic Myeloid Leukemia: The Multi-Center Experience of the Gruppo Di Miglioramento Sicilia-Calabria

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Younger Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Carfilzomib-Lenalidomide-Dexamethasone (KRd) Vs. Lenalidomide-Dexamethasone (Rd) in Newly Diagnosed Fit or Intermediate-Fit Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation (Phase III EMN20 Trial): Analysis of Sustained Undetectable Minimal Residual Disease (MRD)

Efficacy of Frontline Treatment with Initial Low-Dose Tyrosine-Kinase Inhibitors in Elderly Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Salvage Autologous Stem Cell Transplant for the Treatment of First Relapse Multiple Myeloma: Evidence of Its Clinical Role from a Multicenter Italian Study

Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A "Campus CML" Study

Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in Transplant-Ineligible Real-Life Multiple Myeloma Patients: Updated Results of the Randomized Phase IV Real MM Trial

Biological Significance and Prognostic Value of Cytogenetics in 160 Patients with Multiple Myeloma: Predictivity of 13 and/or 14 Monosomies

Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study

Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study

Impact of Gain and Amplification of 1q in Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Based Treatment in the Forte Trial

A Patient with Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia and Multiple Myeloma

Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia

Tumor Circulating Plasma Cells Detected By Flow Cytometric Single Platform Method Correlate with Clinical Response to Therapy and Unfavorable Patients' Characteristics

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia

Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials

Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only